Clinical profile and outcome of large-vessel giant cell arteritis in Japanese patients: A single-centre retrospective cohort study

被引:8
|
作者
Yamaguchi, Eriho [1 ]
Kadoba, Keiichiro [1 ]
Watanabe, Ryu [2 ]
Iwasaki, Takeshi [1 ,3 ]
Kitagori, Koji [1 ]
Akizuki, Shuji [1 ]
Murakami, Kosaku [1 ]
Nakashima, Ran [1 ]
Hashimoto, Motomu [2 ]
Tanaka, Masao [2 ]
Morinobu, Akio [1 ]
Yoshifuji, Hajime [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Rheumatol & Clin Immunol, Kyoto, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Adv Med Rheumat Dis, Kyoto, Japan
[3] Kyoto Univ, Ctr Genom Med, Grad Sch Med, Kyoto, Japan
基金
日本学术振兴会;
关键词
Diagnostic imaging; giant cell arteritis; large vessel involvement; ophthalmic manifestations; TAKAYASU ARTERITIS; INITIAL VALIDATION; ACTIVITY SCORE; VASCULITIS; DAMAGE; INVOLVEMENT; ANEURYSM; IL12B; HLA;
D O I
10.1093/mr/roac013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Recent advances in imaging revealed that giant cell arteritis (GCA) is frequently associated with large vessel involvement (LVI), but they may also contribute to earlier diagnosis and treatment of LV-GCA. We aimed to compare the clinical characteristics of GCA with or without LVI and evaluate its association with clinical outcomes. Method We retrospectively reviewed the medical records of 36 patients with GCA in Kyoto University Hospital. Results Eighteen patients each were assigned to the LVI(+) and LVI(-) groups. Five-year survival rates in the LVI(+) group were better than in the LVI(-) group (p = .034), while five-year relapse-free survival rates were similar between the groups (p = .75). The LVI(+) group required lower doses of glucocorticoid at month 6 (p = .036). Disease activity evaluated with the Birmingham Vasculitis Activity Score at disease onset was higher in the LVI(-) group (p = .014), and the Vasculitis Damage Index score examined at the last visit was higher in the LVI(-) group (p = .011). Conclusion GCA without LVI had more active disease, severer vascular damage, and worse survival, possibly because of ophthalmic complications and their greater glucocorticoid requirement. Our results revisit the impact of cranial manifestations on disease severity and morbidity.
引用
收藏
页码:175 / 180
页数:6
相关论文
共 50 条
  • [31] Cranial giant cell arteritis evolving into early large-vessel vasculitis
    Ghinoi, A.
    Pipitone, N.
    Nicolini, A.
    Salvarani, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (03) : S97 - S100
  • [32] Large-vessel involvement is predictive of multiple relapses in giant cell arteritis
    de Mornac, Donatienne
    Espitia, Olivier
    Neel, Antoine
    Connault, Jerome
    Masseau, Agathe
    Espitia-Thibault, Alexandra
    Artifoni, Mathieu
    Achille, Aurelie
    Wahbi, Anais
    Lacou, Mathieu
    Durant, Cecile
    Pottier, Pierre
    Perrin, Francois
    Graveleau, Julie
    Hamidou, Mohamed
    Hardouin, Jean-Benoit
    Agard, Christian
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13
  • [33] COVID-19 vaccination and large-vessel giant cell arteritis
    Mungmungpuntipantip, R.
    Wiwanitkit, V
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2022, 51 (04) : 329 - 329
  • [34] Progression of large-vessel giant cell arteritis despite tocilizumab treatment
    Elfishawi, M.
    Kaymakci, M.
    Koster, M. J.
    Warrington, K. J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (04) : 984 - 985
  • [35] Takayasu arteritis and large-vessel giant cell arteritis in Italian population. Comprehensive analysis from a single institutional cohort of 184 cases
    Boiardi, Luigi
    Galli, Elena
    Macchioni, Pierluigi
    Muratore, Francesco
    Klinowski, Giulia
    Hunder, Gene G.
    Casali, Massimiliano
    Besutti, Giulia
    Spaggiari, Lucia
    Versari, Annibale
    Croci, Stefania
    Mancuso, Pamela
    Rossi, Paolo Giorgi
    Marvisi, Chiara
    Salvarani, Carlo
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2023, 59
  • [36] Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis
    Kermani, Tanaz A.
    Warrington, Kenneth J.
    Crowson, Cynthia S.
    Ytterberg, Steven R.
    Hunder, Gene G.
    Gabriel, Sherine E.
    Matteson, Eric L.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (12) : 1989 - 1994
  • [37] Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients
    de Boysson, Hubert
    Daumas, Aurelie
    Vautier, Mathieu
    Parienti, Jean-Jacques
    Liozon, Eric
    Lambert, Marc
    Samson, Maxime
    Ebbo, Mikael
    Dumont, Anael
    Sultan, Audrey
    Bonnotte, Bernard
    Manrique, Alain
    Bienvenu, Boris
    Saadoun, David
    Aouba, Achille
    AUTOIMMUNITY REVIEWS, 2018, 17 (04) : 391 - 398
  • [38] Giant-Cell Arteritis: Do We Treat Patients with Large-Vessel Involvement Differently?
    de Boysson, Hubert
    Liozon, Eric
    Lambert, Marc
    Dumont, Anael
    Boutemy, Jonathan
    Maigne, Gwenola
    Silva, Nicolas Martin
    Ly, Kim Heang
    Manrique, Alain
    Bienvenu, Boris
    Aouba, Achille
    AMERICAN JOURNAL OF MEDICINE, 2017, 130 (08): : 992 - 995
  • [39] Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica
    Unizony, S.
    Arias-Urdaneta, L.
    Miloslavsky, E.
    Arvikar, S.
    Khosroshahi, A.
    Keroack, B.
    Stone, J. R.
    Stone, J. H.
    ARTHRITIS CARE & RESEARCH, 2012, 64 (11) : 1720 - 1729
  • [40] Advances in large-vessel imaging and its current place in the diagnosis and follow-up of large-vessel giant cell arteritis
    Liozon, E.
    REVUE DE MEDECINE INTERNE, 2019, 40 : A16 - A19